Comparative Efficacy of Fecal Microbiota Transplantation in Treating Refractory or Recurrent Clostridioides difficile Infection among Patients with and without Inflammatory Bowel Disease: A Retrospective Cohort Study

Comparative Efficacy of Fecal Microbiota Transplantation in Treating Refractory or Recurrent Clostridioides difficile Infection among Patients with and without Inflammatory Bowel Disease: A Retrospective Cohort Study

Blog Article

Clostridioides difficile infection (CDI) worsens inflammatory equi-jec 7 bowel disease (IBD) prognosis.While fecal microbiota transplantation (FMT) is effective for refractory or recurrent CDI (rrCDI), comparative success rates between IBD and non-IBD patients are scarce.This study addresses this gap.

A retrospective cohort study was conducted at Chang Gung Memorial Hospital from April 2019 to October 2023.Patients receiving FMT for rrCDI were categorized into IBD and non-IBD groups.Baseline characteristics and outcomes were compared at one month and one year, with successful FMT defined as the resolution of diarrhea without CDI recurrence.

The study included 88 patients: 30 with IBD and 58 without IBD.The IBD group was younger, with fewer comorbidities.Success rates at one month were similar between groups (IBD: 80.

0% read more vs.non-IBD: 78.9%, p = 0.

908), as were negative toxin tests (IBD: 83.3% vs.non-IBD: 63.

8%, p = 0.174).One-year success rates (IBD: 70.

0% vs.non-IBD: 67.6%, p = 0.

857) and eradication rates (IBD: 94.4% vs.non-IBD: 73.

9%, p = 0.112) were also similar.Poor bowel preparation predicted FMT failure at one month (OR = 0.

23, p = 0.019).No safety issues were reported.

FMT is a safe, effective treatment for rrCDI, demonstrating similar success rates in patients with and without IBD.